August 14, 2020
In recent years, we’ve seen a number of antitrust cases where a pharmaceutical company with a lucrative drug is accused of conspiring with generics companies to keep generic versions of that drug off the market. This class action alleges that Jazz Pharmaceuticals, related Jazz companies, and a long list of other drug companies conspired to delay the introduction to the market of a generic version of the Jazz narcolepsy drug Xyrem.
Case Event File: Jazz Pharmaceuticals Anticompetitive Agreements on Xyrem ComplaintRelated to: Jazz Pharmaceuticals Anticompetitive Agreements on Xyrem Class Action